Infinity Pharmaceuticals, Inc.
INFIQ · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -20.2% | 34.6% | -23.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 39.6% | 39.7% | 39.8% | 24.2% |
| R&D Expenses | $7 | $6 | $7 | $8 |
| G&A Expenses | $4 | $6 | $3 | $0 |
| SG&A Expenses | $4 | $6 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $12 | $10 | $11 |
| Operating Income | -$10 | -$12 | -$10 | -$11 |
| % Margin | -1,735.8% | -1,574.1% | -1,756.5% | -1,528.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$10 | -$11 | -$9 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$11 | -$9 | -$11 |
| % Margin | -1,707.7% | -1,510.9% | -1,699.8% | -1,505.2% |
| EPS | -0.11 | -0.12 | -0.1 | -0.12 |
| % Growth | 8.3% | -20% | 16.7% | – |
| EPS Diluted | -0.11 | -0.12 | -0.1 | -0.12 |
| Weighted Avg Shares Out | 90 | 89 | 89 | 89 |
| Weighted Avg Shares Out Dil | 90 | 89 | 89 | 89 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$11 | -$9 | -$11 |
| % Margin | -1,681.8% | -1,490.4% | -1,672% | -1,483.3% |